Drug Trial Radar · NCT04138836
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Sep 17, 2019
Primary completion
Nov 4, 2019
Study completion Nov 4, 2019
Sponsor
- Lead sponsor
- Bridge Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- KCRN Research, LLC
- First posted
- Oct 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the effect of multiple-dose esomeprazole on the single-dose pharmacokinetics of BBT-877, in healthy adult subjects.
Conditions
- Healthy Participants
Interventions
BBT-877Drug
BBT-877 oral capsule.
MidazolamDrug
Midazolam oral syrup.
ItraconazoleDrug
Itraconazole oral capsule.
EsomeprazoleDrug
Esomeprazole oral capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC (the area under the curve) [Pharmacokinetics]Time frame: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
- Cmax (peak concentration) [Pharmacokinetics]Time frame: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.